These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 12173130)

  • 1. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.
    Jacobs MR
    Clin Infect Dis; 2002 Sep; 35(5):565-9. PubMed ID: 12173130
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia.
    Bhavnani SM; Forrest A; Hammel JP; Drusano GL; Rubino CM; Ambrose PG
    Diagn Microbiol Infect Dis; 2008 Sep; 62(1):99-101. PubMed ID: 18583085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibility of pneumococcal isolates causing bacteraemic pneumococcal pneumonia: analysis using current breakpoints and fluoroquinolone pharmacodynamics.
    Feldman C; Brink AJ; von Gottberg A; Wolter N; de Gouveia L; Perovic O; Klugman KP
    Int J Antimicrob Agents; 2010 Jul; 36(1):95-7. PubMed ID: 20378315
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic options among broad-spectrum beta-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae.
    Jones RN; Fritsche TR; Sader HS
    Diagn Microbiol Infect Dis; 2005 Jun; 52(2):129-33. PubMed ID: 15964501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New quinolones for the treatment of community-acquired pneumonia--contra].
    Egger M
    Dtsch Med Wochenschr; 2003 May; 128(19):1071. PubMed ID: 12736860
    [No Abstract]   [Full Text] [Related]  

  • 7. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?
    Rothermel CD
    Clin Infect Dis; 2004 May; 38 Suppl 4():S346-9. PubMed ID: 15127368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae.
    Rzeszutek M; Wierzbowski A; Hoban DJ; Conly J; Bishai W; Zhanel GG
    Int J Antimicrob Agents; 2004 Aug; 24(2):95-104. PubMed ID: 15288306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic and genotypic characterization of macrolide resistant Streptococcus pneumoniae recovered from adult patients with community-acquired pneumonia in an Argentinian teaching hospital.
    Bonofiglio L; Ojeda MI; de Mier C; Vay C; Famiglietti A; Gutkind G; Mollerach M
    Int J Antimicrob Agents; 2005 Mar; 25(3):260-3. PubMed ID: 15737523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia.
    Metlay JP; Hofmann J; Cetron MS; Fine MJ; Farley MM; Whitney C; Breiman RF
    Clin Infect Dis; 2000 Mar; 30(3):520-8. PubMed ID: 10722438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In vitro resistance rates of Streptococcus pneumoniae and Haemophilus influenzae clinical isolates to the antibiotics used in therapy].
    Uncu H; Colakoğlu S; Turunç T; Demiroğlu YZ; Arslan H
    Mikrobiyol Bul; 2007 Jul; 41(3):441-6. PubMed ID: 17933256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.
    Lynch III JP; Martinez FJ
    Clin Infect Dis; 2002 Mar; 34 Suppl 1():S27-46. PubMed ID: 11810608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotics for childhood community-acquired pneumonia in a region with a high prevalence of penicillin non-susceptible Streptococcus pneumoniae.
    Lee WK; Young BW
    J Antimicrob Chemother; 2005 Sep; 56(3):603-5. PubMed ID: 16040621
    [No Abstract]   [Full Text] [Related]  

  • 14. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002).
    Jones RN; Sader HS; Fritsche TR
    Diagn Microbiol Infect Dis; 2004 Jun; 49(2):147-9. PubMed ID: 15183865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate (2000/125 mg) in adults with community-acquired pneumonia caused by Streptococcus pneumoniae, including penicillin-resistant strains.
    File TM; Garau J; Jacobs MR; Wynne B; Twynholm M; Berkowitz E
    Int J Antimicrob Agents; 2005 Feb; 25(2):110-9. PubMed ID: 15664480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efflux of novel quinolones in contemporary Streptococcus pneumoniae isolates from community-acquired pneumonia.
    Lismond A; Carbonnelle S; Tulkens PM; Van Bambeke F
    J Antimicrob Chemother; 2011 Apr; 66(4):948-51. PubMed ID: 21393137
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparative study of bacteremic and non-bacteremic pneumococcal pneumonia.
    Jover F; Cuadrado JM; Andreu L; Martínez S; Cañizares R; de la Tabla VO; Martin C; Roig P; Merino J
    Eur J Intern Med; 2008 Jan; 19(1):15-21. PubMed ID: 18206596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of tigecycline against Streptococcus pneumoniae, an important causative pathogen of community-acquired pneumonia (CAP).
    Hawser SP
    J Infect; 2010 Apr; 60(4):306-8. PubMed ID: 20144899
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.